A comparison of Campath and Thymoglobulin as part of the conditioning before allogeneic hematopoietic stem cell transplantation.
In vivo T-cell depletion with anti-thymocyte globulin is a commonly used strategy for the prevention of graft-versus-host disease (GVHD) and to avoid rejection after hematopoietic stem cell transplantation (HSCT). We compared 36 patients given Campath (alemtuzumab) as part of the conditioning with a matched cohort of 72 patients receiving Thymoglobulin (TMG). Most patients had a hematologic malignancy beyond first remission. Median age was 55 (1-67). The majority of patients had an unrelated donor (70%) and 82% were given peripheral blood stem cells. Most patients received reduced-intensity conditioning. Graft failure occurred in 8% of the patients in each group. No difference in time-to-engraftment of neutrophils and platelets was found. The cumulative incidence of acute GVHD of any grade was 34% and 53% (P = 0.07), and the incidence of chronic GVHD was 46% and 25% in the Campath and TMG groups, respectively. In multivariate analysis, a low antibody dose was associated with acute and chronic GVHD and Campath was correlated with chronic GVHD. No differences in transplant-related mortality (28% vs. 18%), overall survival (54% vs. 58%), and relapse-free survival (39% vs. 43%) were found between the two groups. No difference in the proportion of T and B lymphocytes during the first year after HSCT was found. TMG and Campath as part of the conditioning result in similar outcome. Campath was associated with less acute but more chronic GVHD.